Bullous Keratopathy Treatment Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Global Bullous Keratopathy Treatment Market is segmented By Disease Type (Pseudophakic Bullous Keratopathy, Aphakic Bullous Keratopathy), By Treatment Type (Hypertonic Saline Drops and Ointments, Contact Lenses, Steroids, Corneal Transplantation, Others), By Sales Channel (Distribution Channel, End-User), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Bullous Keratopathy Treatment Market Overview

Global bullous keratopathy treatment market is expected to reach at a high CAGR during the forecast period 2023-2030.

Bullous keratopathy is also known as corneal edema caused by swelling of the cornea, resulting from the failure of the corneal endothelium to maintain the normally transparent, dehydrated state of the cornea. Most frequently, it is due to corneal endothelial dystrophy or corneal endothelial trauma. The swelling leads to the formation of fluid-filled blisters on the surface of the cornea. Sensitivity when looking at bright lights and significant blurring of vision can result.

The treatment of bullous keratopathy includes hypertonic saline drops and ointments, contact lenses for clear vision, steroid drugs, surgery called corneal transplantation and other treatments. Salty eye drops (hypertonic saline) and salty ointments (hypertonic sodium chloride) are used to draw the excess fluid from the cornea. On occasion, soft contact lenses can be used for a short period of time to decrease discomfort by acting as a bandage to the cornea. If vision is reduced or discomfort is significant and prolonged, corneal transplantation is often done.

Bullous Keratopathy Treatment Market Scope

For more details on this report - Request for Sample

Bullous Keratopathy Treatment Market Dynamics

Increasing demand for therapeutic innovations 

The increasing demand for therapeutic innovations for the treatment of bullous keratopathy is expected to drive the market over the forecast period. If the existing treatments for bullous keratopathy are limited in their effectiveness or are associated with significant side effects, there is a strong incentive for the development of new and improved therapies. This unmet medical need can stimulate investment and innovation in the market.

For instance, in March 2023, Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) approved Aurion Biotech’s allogeneic cell therapy, Vyznova, to treat patients with bullous keratopathy. This approval is believed to be the first for an allogeneic cell therapy for corneal endothelial disease.

Moreover, many clinical trials are going on for the development of novel therapeutics that show better results in inflammatory myositis treatment. For instance, in June 2023, Trefoil Therapeutics is working to improve outcomes in patients who experience corneal edema. A new investigational therapy developed by Trefoil, called TTHX1114, has been shown to stimulate natural cellular processes that protect the corneal cells from damage and improve the rate at which those tissues heal. 

Further, the increasing prevalence of bullous keratopathy, increasing clinical trials, increasing awareness and advancements in the development of novel drugs and therapies are the factors expected to drive the market over the forecast period.

Restraints

Factors such as complications associated with contact lenses, steroids and surgery, the high cost of the treatment of bullous keratopathy and the lack of awareness about the treatment are expected to hamper the market. 

Bullous Keratopathy Treatment Market Segment Analysis

The global bullous keratopathy treatment market is segmented based on disease type, treatment type, sales channel and region.

The hypertonic saline drops and ointments segment accounted for approximately 57.3% of the bullous keratopathy treatment market share

The hypertonic saline drops and ointments segment is expected to hold the largest market share over the forecast period. These are considered as a first-line treatment for the bullous keratopathy. These are often used to reduce corneal edema and alleviate discomfort. Hypertonic saline drops are occasionally used to draw excess fluid from the cornea

For instance, according to the National Institute of Health, topical ocular hypertonic saline seems to be a safe and effective treatment in the management of less severe forms of corneal edema or bullous keratopathy and other corneal disorders such as filamentary keratitis.

Further, hypertonic saline solutions have a higher salt concentration than the natural tears in the eye. When applied topically, they create an osmotic gradient, drawing excess fluid out of the cornea. This helps to reduce corneal edema and relieve the associated pain and discomfort. The primary goal of using hypertonic saline drops and ointments in bullous keratopathy is to alleviate the symptoms, such as pain, photophobia and blurred vision, which are caused by the presence of corneal bullae. 

Bullous Keratopathy Treatment Market Geographical Share

North America accounted for approximately 38.5% of the market share 

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and advanced healthcare facilities. North America especially the United States is known for its strong presence of major players such as pharmaceutical companies and medical device companies. The presence of major players actively performing in clinical trials and research activities, which leads to the launch of innovative treatments.

Furthermore, the presence of advanced healthcare facilities, state-of-the-art medical technology, and highly trained healthcare professionals can significantly impact the bullous keratopathy treatment market. The advanced facilities in the region helps to treat the patients with better patient outcomes by using the advanced technologies.

Bullous Keratopathy Treatment Market Companies

The major global players in the bullous keratopathy treatment market include Alcon Vision LLC, CooperVision, Inc., Bausch & Lomb Inc., Johnson and Johnson, Grevis Pharmaceuticals Pvt Ltd, Rayner Group, SERVIMED INDUSTRIAL S.P.A., MERCK & CO., Inc., AbbVie Inc., Novartis AG and among others. 

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global bullous keratopathy treatment market. During the initial phases of the pandemic, healthcare systems faced tremendous pressure to respond to the surge in COVID-19 cases globally. This results in many elective medical procedures, including non-urgent eye surgeries, being postponed or canceled. This led to delays in the treatment of bullous keratopathy. The pandemic also disrupted the supply chain of these treatment drugs globally.

Why Purchase the Report?

• To visualize the global bullous keratopathy treatment market segmentation based on disease type, treatment type, sales channel and region as well as understand key commercial assets and players
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of bullous keratopathy treatment market-level with all segments
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study
• Product mapping available as excel consisting of key products of all the major players

The global bullous keratopathy treatment market report would provide approximately 61 tables, 57 figures, and 187 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies